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Abstract. Between 2000 and 2010, Me´decins Sans Frontie`res diagnosed and treated 4,831 patients with visceral
leishmaniasis (VL) in the Pokot region straddling the border between Uganda and Kenya. A retrospective analysis of
routinely collected clinical data showed no marked seasonal or annual fluctuations. Males between 5 and 14 years of age
were the most affected group. Marked splenomegaly and anemia were striking features. An rK39 antigen-based rapid
diagnostic test was evaluated and found sufficiently accurate to replace the direct agglutination test and spleen aspiration
as the first-line diagnostic procedure. The case-fatality rate with sodium stibogluconate as first-line treatment was low.
The VL relapses were rare and often diagnosed more than 6 months post-treatment. Post-kala-azar dermal leishmaniasis
was rare but likely to be underdiagnosed. The epidemiological and clinical features of VL in the Pokot area differed
markedly from VL in Sudan, the main endemic focus in Africa.
INTRODUCTION
Visceral leishmaniasis (VL) is a disease caused by protozoa
of the Leishmania donovani complex (L. donovani and
L. infantum). The parasite infects cells of the reticuloendothelial
system and causes progressive splenomegaly, and sometimes
hepatomegaly, lymphadenopathies, wasting, and anemia.1 The
disease is transmitted by female sandflies of the genera
Phlebotomus in the Old World and Lutzomyia in the New
World. It is mainly found in South Asia (India, Bangladesh,
and Nepal) and East Africa, where the most affected countries
are Sudan, South Sudan, Ethiopia, Kenya, Somalia, andUganda.
In East Africa, Phlebotomus orientalis and Phlebotomus martini
are the main vectors of VL2; these two species of sandfly are
found in very different habitats. Phlebotomus orientalis is a dry
season species, associated with the Acacia seyal-Balanites
aegyptica woodlands and black cotton soil found in Sudan and
north-west Ethiopia, whereas P. martini appears to favor more
humid habitats, for example termite mounds.3 The clinical pic-
ture of VL varies according to the setting, reflecting differences
in parasite strains,4 vectors, and hosts. It is important to under-
stand the clinical epidemiology of VL to guide appropriate
clinical diagnosis and management.
The first outbreak of VL to be reported in Kenya was
among soldiers in the north-east of the country in 1942.5
Another outbreak was later described in 1950 in the Kitui
reserve in central Kenya,6 and was followed by further
outbreaks in the Baringo District.7 In the neighboring
North Pokot District, an epidemiological survey undertaken
in 1986 found a prevalence of 3.9% (76 of 1,937) of positive
Leishmania skin tests among the surveyed population (N =
2,139).8 In Uganda, cases of VL were sporadically reported in
the north-east of the country between 1946 and 1957,
resulting in an entomological and clinical study in Amudat
between May 1967 and January 1968.9 This study identified
P. martini as the probable vector. Cases were reported only in
the east of Nakapiripirit District (Pokot County), which
neighbors the North Pokot District of Kenya.
Me´decins Sans Frontie`res (MSF) began working in Amudat
Hospital in Uganda in 1997. It soon became apparent that VL
was endemic, so treatment was made available in 1998 and a
specific VL program deployed in 2000. As the majority of
VL patients were living on the Kenyan side of the border, a
further VL treatment center was opened in Kacheliba in Kenya
in 2006, whereas clinical management of VL in Amudat was
handed over to the Ministry of Health, supported by the Drugs
for Neglected Diseases Initiative (DNDi). The introduction of
rK39 rapid diagnostic tests (RDTs) in 2006 enabled diagnosis
to be decentralized to peripheral health centers. As clinical
and epidemiological characteristics of VL vary according to
geographical setting and have yet to be described in this focus,
we present here the features of VL as observed in a large
cohort of VL patients diagnosed and treated by MSF and
based on our experience gained over the past 11 years.
The specific aims were to describe the epidemiology, clinical
characteristics, and treatment outcomes.
MATERIALS ANDMETHODS
The Ugandan and Kenyan Pokot territory derives its name
from the Pokot tribe living in this border region. Situated on a
semi-arid plateau at an altitude of 1,200 to 1,800 m, it is
bordered by Mounts Moroto, Kadam, and Elgon to the west
and the western wall of the Eastern Rift Valley to the east.
Heavy rains fall between March and June, and sparse rains in
October and November. Villages typically consist of a cluster
of compounds—manyattas—surrounded by a thick fence made
of acacia branches. Several households live in a manyatta.
Households usually keep livestock, (cows, goats, sheep, and
camels) in corrals close to their houses. During the day and
sometimes for longer periods Pokot boys and youths herd the
livestock away from the compounds to graze them.
Analyses were performed on data collected for the routine
monitoring of the project. As experimental investigation was
absent, this analysis was exempted from review by the Ethical
Review Board of MSF. Data on VL patients were collected at
both MSF treatment facilities (Uganda’s Amudat Hospital
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and Kenya’s Kacheliba Health Center, Kenya) on standard-
ized patient files that changed only slightly over the years.
In addition to diagnosed VL patients, data were also collected
at Amudat Hospital on all patients with suspected VL, whereas
in Kacheliba data collection was restricted to confirmed cases
of VL.
At Amudat Hospital, symptoms were recorded at the
time of admission as open questions, whereas at Kacheliba
Health Center symptoms were systematically checked and
recorded during consultation. Nutritional status was addressed
differently according to the age group. In children £ 5 years
of age, severe malnutrition was defined as a z-score for
weight-for-length/height below −3 or the presence of oedema,
and moderate malnutrition as a z-score for weight-for-length/
height between −3 and −2. For children between 6 and 19 years
of age severe malnutrition was defined as a z-score for body
mass index (BMI)-for-age below −3 andmoderate malnutrition
as a z-score for BMI-for-age between −3 and −2. For adults,
severe malnutrition was defined as a BMI of < 16 kg/m2 and
moderate malnutrition as a BMI between 16 and 17 kg/m2.
Diagnosis of VL was based either on demonstration of the
parasite in spleen tissue obtained by spleen aspiration,10 on
a positive direct agglutination test (DAT), or on a RDT
detecting antibodies against rK39 antigen.
Treatment of primary VL relied mostly on antimonials,
meglumine antimoniate, or sodium stibogluconate (SSG), at
an intramuscular dose of 20 mg/kg for a period of 30 days.
Amphotericin B deoxycholate (1 mg/kg administered on alter-
nate days for 15 days) was temporarily used as first-line treat-
ment in Amudat during a stock-out of antimonials, with no
difference in outcome compared with antimonials.11 In a ret-
rospective analysis of patients treated between 2000 and 2006,
patients with a high risk of death during treatment with anti-
monials were identified,12 leading to recommend amphotericin
B deoxycholate and later AmBisome as the first-line treatment
of vulnerable patients (human immunodeficiency virus [HIV]
co-infected patients, pregnant women, patients > 45 years of
age, and patients in very poor general health).
A VL suspect case was defined as a patient presenting with
a history of fever lasting at least 2 weeks and splenomegaly
(defined as a palpable spleen below the costal margin on the
medioclavicular line) and/or wasting (or a recent history of
weight loss). A primary VL case was defined as a suspect case
without any history of previous VL treatment and either 1)
positive parasitology (demonstrated parasites in a lymph node,
spleen, or bone marrow aspirate), 2) positive direct DAT
(titer > 1:12800), or 3) a positive rk39-based rapid test
(DiaMed IT-Leish, DiaMed GmbH, Cressier, Switzerland).
Relapse VL cases were defined as patients with a history of
treated VL and parasites found in a lymph node, spleen,
or bone marrow aspirate. Post-kala-azar dermal leishmaniasis
(PKDL) cases were defined as patients previously treated
for VL, presenting with a macular and/or nodular rash.
In Uganda, village names were entered manually in the
Excel (Microsoft Corp., Redmond, WA) sheet for each patient,
resulting in different spellings for the same locations. In the
database used in Kenya, the list of possible villages was
predefined, based on administrative divisions, which reduced
the risk of errors. The GPS (Global Positioning System) coor-
dinates of the villages of residence of VL cases seen at
Amudat Hospital and Kacheliba Health Center were collected
in 2007, and were combined with the number of VL cases seen
between 2000 and 2010 using the Quantum GIS software ver-
sion 1.7.0. High-resolution data on elevation were derived from
data collected by the shuttle radar topography mission across
Africa at 90 m + 90 m spatial resolution (http://srtm.usgs.gov).
In the first years of the project, data were recorded in
an Excel spreadsheet. Since 2006, a specific Access-based
program was developed to simplify data entry. After data
cleaning, the two treatment center databases were merged
and analyzed using the Stata 11 software (StataCorp LP,
College Station, TX). All the results were stratified by treat-
ment center. Data were pooled if the results were comparable
between centers; otherwise, results are presented by treat-
ment center. Tests of hypotheses were based on c2 for cate-
gorical variables and t test for continuous variables, using a
level of significance of 0.05. Some patients were present with
more than one record in the database, if they had received
more than one course of treatment. For the description of
primary VL cases, 9 cases from Amudat and 12 cases from
Kacheliba were excluded because the diagnosis of VL was not
confirmed (incomplete laboratory results or diagnosis based
on clinical features only).
RESULTS
Patient characteristics. At Amudat Hospital, there were
4,428 admissions for VL investigation between 2000 and
Figure 1. (Top) Admissions for primary visceral leishmaniasis to
Amudat and Kacheliba Treatment Centers, Pokot area, Uganda and
Kenya. (Bottom) Monthly admissions, by year, from January 2000 to
December 2010.
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2006, including 2,461 primary VL, 56 relapses, 4 PKDL, and
1,907 cases ultimately viewed as non-VL cases. In Kacheliba,
2,301 cases of leishmaniasis were diagnosed between 2006 and
2010, including 2,144 primary VL, 81 relapses, and 75 PKDL.
Figure 1 presents the monthly admissions for primary VL, by
year, 2000 to 2010. The number of primary VL cases treated
by MSF peaked in the years 2005 to 2007. The catchment
area, after increasing during the first few years, shifted over
to the Kenyan side of the border after 2006, and remained
very similar thereafter (data not shown). The number of
monthly admissions by year (Figure 1) showed no marked or
consistent seasonal fluctuations.
At Amudat Hospital, 68% out of the 2,452 primary VL
cases were coming from Kenya and 25% from Uganda,
although the country of residence was not given for the
remaining 7%. In Kacheliba, almost all of the 2,130 cases
(97%) were from Kenya. We were able to collect GPS coor-
dinates for 149 villages (123 in Kenya and 26 in Uganda),
representing the stated location of residence for 92% of the
total number of cases. Figure 2 shows the number of cases
treated by village of residence.
In both treatment centers, young males were the most
affected group (Table 1). Male patients were slightly older than
female patients (P < 0.001). Pregnant women represented
0.7% of all patients (N = 34). Patients reported earlier at
Kacheliba than at Amudat (Table 2; P < 0.001). Although
details of symptoms were not consistently recorded in Amudat,
the most frequently reported symptoms in Kacheliba (in addi-
tion to fever, which was part of the case definition) were
weight loss (87.8%), loss of appetite (86.8%), spleen enlarge-
ment (77.1%), nose bleeding (21.9%), vomiting (16.5%),
headache (14.6%), abdominal pain (13.0%), abdominal swell-
ing (11.4%), and diarrhea (8.5%). On clinical examination,
mean spleen size was 12.3 cm below the costal margin in
Amudat (SD 4.2 cm) and 11.4 cm in Kacheliba (SD 4.4 cm;
t test P < 0.001). In Kacheliba, an enlarged liver was reported
in 13.5% out of 2,130 cases, although lymph nodes were
enlarged in only 1.3% of cases. Other signs such as pallor,
oedema, and jaundice were reported in respectively 45.8%,
8%, and 2.3% of cases. More than half of the patients were
malnourished on admission, with 24.7% severely malnour-
ished and another 27.6% moderately malnourished.
Testing for HIV was systematically proposed in Kacheliba
after the introduction of AmBisome treatment of HIV-VL
co-infected patients. Out of 740 patients tested for HIV,
2.3% (N = 17) were found to be positive. In Amudat, blood
Figure 2. Map of number of primary visceral leishmaniasis cases treated between 2000 and 2010 in Amudat and Kacheliba Treatment
Centers, per village of residence. (a total of 4,216 cases with Global Positioning System [GPS] locations out of 4,582 cases; 137 cases from
Baringo District are outside the map area).
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from 206 VL patients anonymously screened for HIV in 2003
found 1.4% prevalence. Patients were systematically screened
for malaria using a blood smear examination. Over the years,
the prevalence of positive malaria slides varied between 3.8%
and 21.4% in Kacheliba, and between 5.3% and 34.4% in
Amudat, with no clear trend identified over time. The mean
hemoglobin level was 7.9 g/dL (SD 1.8 g/dL).
Laboratory diagnosis. The procedure for confirming VL
diagnosis evolved over the years. Initially, diagnosis was based
on spleen aspirates, which were performed on over 400 patients
with no major bleeding complication. Spleen puncture was
rapidly omitted for patients with negative DAT (£ 1:100) or
high DAT titers (³ 1:51,200), but continued to be performed
along with DAT in all other patients up to August 2001. The
DAT titers were then compared with results of a microscopic
reading of spleen aspirates, defining the DAT threshold titers
later used in the program: < 1:1,600 (negative), 1:3,200–1:12,800
(borderline) and ³ 1:25,600 (positive). The resulting diag-
nostic algorithm used from September 2001 to February 2005,
resulted in a dramatic decrease in the number of spleen
punctures performed, from 35.1% to 11.7% of suspected VL
cases (Table 3).
Following the completion of a diagnostic evaluation
study,13 the rK39 DiaMed IT LEISH was fully deployed as
first-line diagnostic test in March 2005 (Table 3). The DAT
was still required for patients with a negative rk39 test
because of the relatively low sensitivity reported elsewhere in
East Africa.14,15 This new algorithm (Figure 3) led to a further
reduction in the number of spleen aspirates performed
(0.2%), and a sharp decrease in the number of DAT (17.1%)
(Table 3).
Treatment outcomes. The overall case-fatality rate in VL
patients was 1.0% in Kacheliba as compared with 3.0% in
Amudat (P < 0.001; Table 4). Case fatality rates were different
for patients treated with antimonials, i.e., 1.0% in Kacheliba
versus 2.6% in Amudat (c2 P < 0.001), although it was
not significantly different in the other treatment groups. In
October 2008, AmBisome was introduced in Kacheliba, for
use in the case of 1) treatment failure (non-response or relapse),
2) intolerance to antimonials (e.g., intractable vomiting), and
3) contraindication(s) for antimonials. Initially, the total dose
was 20 mg/kg, as previously recommended by the World
Health Organization (WHO).16 However, a high proportion
of patients treated with this regimen relapsed (6 of 46; 13.0%),
which concurred with observations made by other MSF pro-
grams in East Africa.17,18 This led to an increase in total dose
to 30 mg/kg (5 mg/kg/day IV + 6 doses) from November 2009,
resulting in a lower proportion of relapses (2/51 = 3.9%;
P = 0.075).
Relapses. The ratio of relapses versus primary VL cases
was 2.4% in Amudat (N = 58), compared with 3.8% in
Kacheliba (N = 81). Active follow-up was not implemented,
resulting in low 6-month follow-up rates: 16.7% in Kacheliba
and < 3% in Amudat, where it was not a priority of the
program. The median period between initial treatment and
relapse was 186 days (range 11–543). In Kacheliba, relapse
patients had been previously treated with antimonials
(60.5%), amphotericin B deoxycholate (18.5%), AmBisome
(12.3%), or unknown (8.6%), whereas in Amudat they had
received antimonials (55.2%), amphotericin B deoxycholate
(19%), or an unknown drug (25%). Out of 32 relapse patients
tested for HIV in Kacheliba, four were positive (12.5%).
PKDL. In Amudat a single patient was diagnosed with
PKDL and admitted four times because of recurrences, some-
times accompanied by VL or post-kala-azar ocular leishman-
iasis (uveitis). In all, between 2000 and 2002 he received five
courses of treatment during four admissions. He died during
the last course of treatment probably caused by antimonial-
induced pancreatitis. In Kacheliba, 75 PKDL cases were
treated, with a PKDL to primary VL ratio of 3.5%. Previous
treatment consisted of antimonials (66 of 75, 88%) or was
unknown (9 of 75, 12%). No PKDL was reported after
amphotericin B deoxycholate or AmBisome treatment.
There was an increase over time in PKDL cases in Kacheliba
treatment center.
DISCUSSION
A total of 4,605 primary VL, 137 relapses, and 79 PKDL
patients were treated by MSF in Amudat (Uganda) and
Kacheliba (Kenya) between 2000 and 2010. The VL in the
Pokot area is a disease that mainly affects young males,
although both genders and all age categories are affected.
This probably reflects differences in exposure to sandflies.
Table 2
Duration of symptoms in primary visceral leishmaniasis patients,
by treatment center, Pokot area, Uganda and Kenya
Kacheliba
(N = 2,130)
Amudat
(N = 2,452)
n (%) n (%)
Duration of illness
(in months)
0–1 month 1,216 (57.1) 830 (33.8)
2 months 527 (24.7) 771 (31.4)
3–5 months 326 (15.3) 732 (29.8)
³ 6 months 59 (2.8) 66 (2.7)
Missing 2 (0.1) 53 (2.2)
P value < 0.001
Table 1
Distribution of primary visceral leishmaniasis cases, by age group and gender, Amudat and Kacheliba Treatment Centers, Pokot area, Uganda
and Kenya
Age group (in years)
Female Male Not known Total
n (%) n (%) n n (%)
< 1 6 (0.4) 1 (0.0) 0 7 (0.1)
1–4 303 (21.3) 375 (11.9) 2 680 (14.8)
5–14 601 (42.3) 1413 (44.9) 2 2,016 (44.0)
15–44 446 (31.4) 1239 (39.4) 7 1,692 (36.9)
45–99 50 (3.5) 110 (3.5) 1 161 (3.5)
Not known 15 (1.0) 10 (0.3) 1 26 (0.6)
Total (%) 1,421 (31.0) 3,148 (68.7) 13 (0.3) 4,582 (100.0)
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There is no clear seasonal pattern. The incidence appeared to
fluctuate slowly over the years, but we did not see marked
epidemic surges as described in Sudan.19 In recent years, the
annual number of new VL cases diagnosed in Kacheliba has
stabilized at around 400 cases, suggesting that passive case-
finding of VL patients is not sufficient to control the disease,
despite the implementation of decentralized diagnosis in
several sites. This could either be because most of the trans-
mission occurred either before or at the beginning of the
symptomatic phase, or that many cases remained untreated,
maintaining a constant parasite reservoir.
The clinical picture of VL in the Pokot area differed from
Sudan. Lymph node enlargement was not as pronounced.
The average spleen size was larger than in Sudanese patients
(12 cm versus 5–7 cm).20,21 However, a longer period before
seeking treatment may partly explain this difference.22 Inter-
estingly, spleen size was also large among clinically suspected
VL cases finally not diagnosed with VL (data not shown).
Other diseases resulting in massive splenomegaly such as
hyperactive malarial splenomegaly could be prominent in
this region. The introduction of rK39 RDT as the first-line
diagnostic test allowed to simplify the diagnostic algorithm
Table 3
Diagnostic tests to diagnose primary visceral leishmaniasis (VL), by diagnostic algorithm, Amudat Treatment Center, Uganda
DAT validation
(up to September 2001)
DAT-based algorithm
(up to March 2005)
rK39-based algorithm
(from March 2005 onwards)
Number of tests Primary VL diagnosed Number of tests Primary VL diagnosed Number of tests Primary VL diagnosed
n (%) n (%) n (%)
rK39 RDT* 0 0 (0.0) 0 0 (0.0) 1,729 1,113 (95.1)
DAT* 530 147 (66.2) 1,892 956 (89.9) 303 53 (4.5)
Spleen aspirates 187 71 (32.0) 224 100 (9.4) 4 3 (0.3)
Total suspected cases 532 222† (100.0) 1,919 1,063† (100.0) 1,772 1,170† (100.0)
*DAT = direct agglutination test; RDT = rapid diagnostic test.
†Five primary VL cases diagnosed by lymph node puncture and seven on clinical grounds.
Figure 3. Diagnostic algorithm of visceral leishmaniasis used by Me´decins Sans Frontie`res since March 2005 at Amudat and Kacheliba
Treatment Centers, Pokot area, Uganda and Kenya.
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and decrease the use of more demanding (DAT) or invasive
(spleen aspirate) procedures. However, the limited sensitivity
of rK39 RDT in East Africa remains a severe constraint.14
Relocating the MSF treatment facility from Amudat to
Kacheliba closer to the center of the endemic area led to
earlier patient presentation. The proportion of Ugandans
seen in Kacheliba was lower compared with Amudat, because
Ugandans still accessed treatment in Amudat Hospital after
2006. The introduction of rK39-based rapid tests in peripheral
sites made diagnosis more accessible, but led to neither earlier
presentations nor better treatment outcomes (data not shown).
The limited quality and scope of services in peripheral health
centers and the good reputation of VL treatment centers were
important factors in attracting patients. For example, half of
the VL cases originating from one of the decentralized diag-
nostic sites (Sigor Subdistrict Hospital) had traveled a long
distance to Kacheliba treatment center for testing.
We observed a lower case-fatality rate for primary VL
cases in Kacheliba compared with Amudat, but it is not possi-
ble to differentiate the impact of earlier presentation, the
different treatment regimen (e.g., liposomal amphotericin B
for vulnerable groups), and other unmeasured differences in
case management. The optimal dosage of AmBisome for VL
treatment in East Africa is not known. Despite the methodo-
logical limitations (retrospective review of sequential cohorts)
and the limited proportion (29.6%) of patients followed at
6 months post-treatment, our data suggest that a total dose of
30 mg/kg of AmBisome is more effective than 20 mg/kg.
The median period to diagnosis of relapse was 6 months
after initial treatment (after a median period of symptoms of
1 month). A 6-month follow-up period may therefore not be
appropriate to define final cure for the Pokot setting. The pro-
portion of PKDL cases was very low compared with Sudanese
patients, 50% of whom develop PKDL.22 Population-based
data are not available, which may severely underestimate the
true incidence of PKDL. We observed an increasing number
of PKDL cases identified over time, which probably reflects
the improved post-treatment follow-up. Sodium stibogluconate-
paromomycin (SSG-PM) combination treatment was intro-
duced as the first-line treatment in Kacheliba in December
2011. This may further reduce the incidence of PKDL, as
suggested by data from the randomized trial conducted in East
Africa comparing SSG with SSG-PM.23
The simplification of diagnostic algorithm and optimization
of treatment regimen were crucial first steps to improve
access to quality VL care in the Pokot area. However, the
impact and sustainability of these achievements will be mini-
mal and short-lived without increased commitment of Kenyan
public health authorities at both the national and local level.
Pokot people live in a remote area and have little political
voice. Even the basics of VL control, i.e., availability of diag-
nosis and treatment, were not secured in the last decades
because of lack of a national VL control program and dedi-
cated resources. Fortunately, there has been some positive
development over the last years. A national VL control pro-
gram was recently released by the Ministry of Health and the
revision of VL national guidelines was completed in 2012. The
rK39 RDT for diagnosis and the combination SSG/PM were
included in the revised guidelines. To ensure that VL diagno-
sis and treatment are routinely accessible to the marginalized
population of the remote Pokot area, however, the Kenyan
government will need to show its commitment to the national
VL control program and provide it with sufficient funding.
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